BioCentury
ARTICLE | Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

July 11, 2019 8:45 PM UTC

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc. (NASDAQ:GILD). Shaw, who oversaw the launches of rheumatoid arthritis drug Olumiant baricitinib and migraine drug Emgality galcanezumab-gnlm at Lilly, will be succeeded by Patrik Jonsson, president and general manager of Lilly Japan. The pharma also said SVP and general counsel Mike Harrington will retire at year end; a search for his successor is underway.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) hired former Shire plc CFO Jeff Poulton as EVP and CFO. He succeeds CFO Manmeet Soni, who will step down on Aug. 12 to pursue other opportunities. ...